Our pipeline “IMPACT” (IMProving Personalized Adoptive Cell Therapy) allows us to identify tumor-reactive T cells and isolate unique T cell receptors (TCR) from each patient’s tumor.
Using IMPACT we generate the product “UNIPACT” (UNIversal Personalized Adoptive Cell Therapy) using patient-specific TCR-transgenic T cells via our nanoSMAR vector.
Tcelltech has also developed peptide vaccines targeting the two most common mutations in incurable brain tumors (IDH1R132H and H3K27M).
Our IDH1R132H SCA-VAC has completed Phase I trial (32 patients, 21 grade 3, 11 grade 4), meeting both primary endpoints.
We currently prepare IDH1 for out-licensing to industrial partners.
© 2022 Tcelltech GmbH. All rights reserved.
Responsible Provider in accordance with § 5 of the German Telemedia Act (TMG):
T + 49 178 730 730 2
Michael Platten, Richard Harbottle, Edward Green, Mathias Turwitt
Commercial register/register number
District Court of Mannheim HRB 745 600
not yet available